[1] ARMSTRONG D K,BUNDY B,WENZEL L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J].N Engl J Med,2006,354:34-43.
[2] BARLIN J N,DAO F,ZGHEIB N B,et al.Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian,fallopian tube,and primary peritoneal cancer[J].Gynecologic Oncology, 2012,125:621-624.
[3] JAABACK K,JOHNSON N,LAWRIE T A,et al.Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer[J].Cochrane Database Syst Rev,2006(1):CD005340.
[4] PEPA C D,TONINI G,PISANO C,et al.Ovarian cancer standard of care:are there real alternatives?[J].Chin J Cancer,2005,34(1):17-27.
[5] TEWARI D,JAVA J J,SALANI R,et al.Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer:a gynecologic oncology group study[J].J Clin Oncol,2015,33(13):1460-1466. |